Head and neck squamous cell carcinoma (HNSCC) encompasses multiple sites of origin -the oral cavity, oropharynx, and larynx -with diverse drivers of carcinogenesis and diverse clinical outcomes. Oropharyngeal cancer, the subtype of HNSCC that originates in the oropharynx, is associated with human papillomavirus (HPV) infection, alcohol use, and tobacco use, and is the 13th most common diagnosed cancer and the 15th most common cause of cancer death for adults in Canada. 1 An estimated 4,400 Canadians (2,900 men and 1,450 women) were diagnosed with HNSCC in 2015, and 1,200 Canadians will die of the disease. [2] [3] [4] [5] In 2010, 210 Canadians (170 men and 40 women) were diagnosed with oropharyngeal cancer. 6
Research Questions
1. What is the comparative clinical effectiveness of primary surgery (with or without adjuvant radiotherapy and chemotherapy) versus primary chemoradiotherapy (with or without salvage surgery) for the treatment of adults with a diagnosis of locally advanced oropharyngeal cancer? 2. What is the cost-effectiveness of primary surgery (with or without adjuvant radiotherapy and chemotherapy) for the treatment of adults with a diagnosis of locally advanced oropharyngeal cancer? 3. What is the cost-effectiveness of primary chemoradiotherapy (with or without salvage surgery) for the treatment of adults with a diagnosis of locally advanced oropharyngeal cancer?
Methods
The protocol for this systematic review was written a priori and will be followed throughout the review process.
Search Strategy
A limited literature search was conducted on key resources including PubMed, OVID, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, and Canadian and major international health technology agencies, as well as with a focused Internet search. Filters were applied to limit the retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, and economic studies. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2006 and October 6, 2016. A supplemental search was performed, which was limited to English-language documents published from January 1, 2001 to November 17, 2016. See Appendix 1 for the detailed search strategy.
Selection Criteria
Selection criteria are outlined in Table 1 . Intervention Concurrent primary chemoradiotherapy (with or without salvage surgery)
Comparator Primary surgery (with or without adjuvant radiotherapy and chemotherapy)
Outcomes

Oncologic outcomes
Overall survival, recurrence-free survival, local-regional control (LRC, freedom from local progression)
Functional outcomes
Rate of percutaneous feeding tube dependence at 2 years; rate of tracheostomy dependence at 2 years 
Screening and Selecting Studies for Inclusion
Two reviewers (CH and KS) will independently screen the titles and abstracts of all citations retrieved from the literature search and, based on the selection criteria, will order the full text of any articles that appear to meet those criteria. The reviewers will then independently review the full text of the selected articles, apply the selection criteria to them, and compare the independently chosen included/excluded studies. Disagreements will be resolved through discussion until consensus is reached. Duplicate publications of the same study will be excluded unless they provide additional outcome information of interest. The study inclusion/exclusion form is provided in Appendix 2. The study selection process will be presented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart. 10 Articles will be excluded if they did not meet the selection criteria in Table 1 , if they were published prior to January 2001, or if they are duplicate publications of the same study. A list of excluded studies, with reasons for exclusion, will be provided for each research question.
Data Extraction
A data extraction form for the review will be designed a priori to document and tabulate relevant study characteristics. Data will be extracted independently by reviewers (CH and KS), and any disagreements will be resolved through discussion until consensus is reached. Study authors will be contacted in case of missing or unclear data. A draft of the a priori data extraction form for the clinical and cost studies is provided in Appendix 3. A calibration exercise will be conducted to ensure consistency in data extraction.
Methodological Assessments
The quality of clinical studies and cost evaluations will be assessed using Downs and Black and Drummond checklists, respectively. Quality assessment will be done by the lead researcher, and verified by a second researcher. Any disagreements will be resolved through discussion until consensus is reached. Studies will not be excluded based on methodological assessments, but assessments will be used to explain any potential differences across study results.
Summary of Evidence
Description of Study Characteristics and Findings
For each question, a narrative summary will be undertaken to report on the quantity of studies by design, intervention, comparator, settings, and outcome measures, where applicable. Tables will accompany the narrative summary, to ensure the consistency of the presented information across all studies and facilitate study comparisons by the reader.
Description of Methodological Assessments
A narrative summary of the results of the methodological assessments will be presented separately for each research question, including an overall impression of the quality of included studies. Tables outlining the strengths and limitations of each study will accompany the narrative summary, to ensure consistency of presented information across all studies and facilitate study comparisons by the reader. Separate tables will be created for each study design, or tabulated data will be separated within the same table by the use of subheadings.
Data analysis methods
Tables will be created to summarize quantitative findings for each outcome listed in Table 1 . Data will be synthesized separately for each question, by outcome.
Head-to-head trials between the two treatment strategies will be included. Since discrepancies in patient demographics, such as clinical stage and comorbidities between the two intervention groups, may lead to bias in outcomes, meta-analyses will be performed only from data from randomized controlled trials (RCTs); in that case, results will be pooled. If meta-analysis is deemed inappropriate owing to lack of RCTs, or the heterogeneity of the clinical trials and methodological characteristics of included studies, a narrative summary of the included study findings will instead be constructed. Clinical experts may be consulted to determine whether important clinical heterogeneity exists.
If meta-analysis is deemed appropriate, meta-analyses will be carried out using Cochrane Review Manager software to derive pooled estimates of interest. A random-effects model will be used. Forest plots will be presented for all evidence syntheses to supplement reported estimates.
Time-to-event data (e.g., hazard ratios or continuous time-to-event measurements) will be presented, where appropriate, and will be pooled according to the methods described by Tierney et al. 11 If pooling is deemed to be inappropriate, time-to-event data will be presented in tabular format and described narratively.
Analyses of dichotomous outcomes will be summarized using relative risks and 95% confidence intervals (CIs), and analyses of continuous outcomes will be summarized using mean differences and 95% CIs. Findings will be reported as "not statistically significant" if the CI of the overall estimate includes unity for dichotomous outcomes, or if the CI of the overall estimate includes null for continuous outcomes. The chi-square test will be used to assess effect size variance, with P < 0.10 indicating significant heterogeneity across trials.
Planned subgroup analyses based on use of additional treatments (i.e., surgery alone or surgery with adjuvant chemotherapy or radiotherapy; primary chemoradiotherapy with or without salvage surgery), surgical approach, chemotherapy agent (cisplatin or cetuximab), and based on patient characteristics such as HPV status, smoking habit, and alcohol use will be performed when sufficient data are available. When significant heterogeneity is identified and sufficient data are available, further subgroup analyses will be made to identify the primary sources of heterogeneity. Additional sensitivity analyses dealing with outlying data points, study quality, study size, and other factors will also be considered to establish the robustness of findings.
For the economic review, costs and cost-effectiveness outcomes of primary surgery with or without adjuvant chemoradiotherapy, and of primary chemoradiotherapy with or without salvage surgery from the available evidence, will be summarized and reported narratively and in tables. No primary economic evaluation will be performed.
Areas for Potential Amendments
If amendments are required at any time during the study, reasons for changes will be recorded in a study file and subsequently reported within the final study report. If necessary, a rescreening of the previous literature search or an updated literature search will be performed to capture additional data according to the amendments.
Study
Types:
Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, controlled clinical trials, cohort studies, economic studies, and guidelines Limits:
Publication date limits:
Randomized controlled trials, controlled clinical trials, cohort studies, and economic studies -2001present Health technology assessments, systematic reviews, meta-analyses and guidelines -2001-present "yes" (1-5 inclusive): include study and order full paper_____ at least one "can't tell" and others "yes" for 1-5: order full paper for further review_____ "no" (any 1 -5): exclude study 
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